265 Antibody Drug Conjugates Companies - Worldwide

Shenyang, China

关于三生制药集团 三生制药集团是一家集研发、生产和销售为一体的生物制药领军企业，致力于以高品质的药品提高患者生存质量，为人类健康造福。目前，集团拥有80余项国家发明专利授权，30余种上市产品，覆盖肿瘤、自身免疫、肾病、代谢及皮肤科等治疗领域。集团拥有抗体药物国家工程研究中心以及生物药和化药双平台的4大研发中心，共有25种在研产品，其中16种作为国家一类新药正在研发，并拥有符合GMP标准的6大生产基地。未来，三生制药集团将继续秉持"珍爱生命、关注生存、创造生活"的理念，全力打造全球领先的中国生物制药企业。 About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of "Care for Life, Cherish Life, Create Life" to create a world's leading bio-pharmaceutical company in China.

Hayward, California

Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.

Emeryville, California, United States of America

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

North Chicago, Illinois, United States

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Seongnam-si, Gyeonggi-do, South Korea

ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com

San Diego, California, United States

Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities. The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties. Users of AlivaMab Mouse include the world’s largest pharmas, public and private biotechs, and leading academic institutions. AlivaMab Mouse-derived antibodies in clinical development span formats including IgG, multispecific, ADC, and CAR. Many partners use AlivaMab Mouse at Ablexis’ sister company, AlivaMab Biologics, a leading provider of services in antibody drug discovery, engineering, and protein sciences. Visit us at www.ablexis.com to learn more. For inquiries about licensing the AlivaMab Mouse, contact us at info@ablexis.com.

1 Innovation Way, Newark, DE 19711, USA

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

Jiangsu Province, China

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

Copenhagen, Denmark

Adcendo is a Danish clinical-stage biotech company headquartered in Copenhagen, dedicated to the development of highly differentiated First-In-Class Antibody-drug conjugates (ADCs) for treatment of solid tumors. In November of 2024, the company announced the closing of a USD 135m series B financing round. With a total sum of USD 240m raised since 2021 and under the leadership of a highly experienced management team, Adcendo is moving forward a growing and highly differentiated pipeline of drug candidates into the clinic. Read more at www.adcendo.com

San Diego, California, United States

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

Lausanne, Switzerland

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

Amsterdam, Netherlands

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases.

Lugano, Switzerland

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

Morrisville, North Carolina, United States

Aerial BioPharma LLC is a pharmaceuticals company based out of Aerial Center Executive Park, 9001 Aerial Center Parkway, Suite 110, Morrisville, NC, United States.

Ghent, Belgium

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Office 507, 25 Ttukseom-ro 1-gil, Seongdong, Seoul Teugbyeolsi, KR, 04778

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase. Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity. AIGEN Sciences will revolutionize AI-based drug discovery.

Itasca, Illinois, United States

Ajinomoto is a global leader in the research, development, manufacture and sale of amino acid-based products for the pharmaceutical, nutraceutical, sports nutrition, health and beauty industries as well as food ingredients and consumer food products.

Cambridge, United Kingdom

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Zhongshan, China

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

Paris, France

Founded in 2017 and headquartered in Paris, France, Alderaan Biotechnology works with world-class teams in the fields of immunomodulation and immunotherapy of cancer focusing on the development of monoclonal antibodies with technologies aiming at Treg depletion in solid tumours. The company raised €1.5M ($1.7M) in 2017 from co-founder AdBio partners and €18.5M ($20.7M) in 2019 from AdBio partners and Medicxi. Alderaan Biotechnology works in partnership with the French national Institute for health and medical research (INSERM) and with the Institut Paoli Calmettes, Marseille, France.

Allschwil, Basel-Country, Switzerland

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

Basel, Switzerland

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis.  Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1.  Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver.  The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).  Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

San Carlos, California, United States of America

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Shanghai, CN

Founded in 2023 and based in Shanghai, China, Allink Biotherapeutics is a biotech company dedicated to expediting the development of a diverse pipeline of FIC/BIC therapeutic candidates for oncology and immune diseases. Our goal is to harness our proprietary bispecific antibody and ADC technology platforms, along with efficient execution and business collaboration , to address critical unmet clinical needs.

Suzhou, China

Alphamab Oncology (Stock code: 9966.HK) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and we are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.

62, Yuseong-daero 1628beon-gil, Yuseong-gu, Daejeon 34054, KR

ALTEOGEN Inc., Daejeon(fifth-largest metropolis)-based in South Korea, is a leading biopharmaceutical company with a leading edge pipeline of novel biologics such as next generation biobetters including long-acting therapeutic proteins, Antibody-Drug Conjugate (ADC) therapeutic antibodies and monoclonal antibody biosimilars. The company was founded in 2008 and listed in KOSDAQ stock market (KRX:196170). Our innovative NexP™ fusion technology is applied to various proteins and peptides to allow longer activities in human beings. Long-acting human Growth Hormone, long-acting exenatide (for diabetes) and long-acting Factor VIIa (for hemophilia) are developed with the NexP™ fusion technology. Our proprietary ADC technology, NexMab™ ADC technology is well suited for the targeted therapy for the cancer drugs with lower side effect and better efficacy. With this NexMab™ ADC technology, we are developing ADC therapeutics for breast/gastric cancer and ovarian cancer. Alteogen's mostly distinguished Hybrozyme™ technology to a human hyaluronidase, which has been widely used to improve the absorption of drug biologics delivered via subcutaneous injection. The novel human hyaluronidase based on Hybrozyme™ technology showed improved enzymatic activity and thermal stability. Based on long and rich experiences, Alteogen has quickly developed its own cell lines with high expression, efficient process (upstream and downstream), and optimized analysis methods for monoclonal antibody biosimilars including Herceptin preparing for the phase 3 trials upon completion of global phase 2 testing, SC formulation of Herceptin biosimilar as well as working on Eylea biosimilar.

Boston, MA, United States

Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments.

La Jolla, California, United States of America

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California.

Eggenstein-Leopoldshafen, Germany

Zedira is specialist and global brand for transglutaminase. More than 200 specialty reagents for transglutaminase-related R&D. Researchers from academia and industry (including 12 of the top 15 big pharma companies) benefit from Zedira’s cutting edge products – and in an increasing manner – from customised services. Solutions for site specific labeling of proteins using transglutaminases form Zedira’s latest product field.

Downtown Redwood City, California, United States

AmMax is a private biotechnology company focused on the clinical development of innovative cancer therapeutics. The Company strategically acquires oncology assets to develop into innovative and clinically meaningful products. It leverages its expertise in translational science to pursues first-in-class or best-in-class therapeutics with significant market opportunity. The company is focused on leveraging its CSF1R mAb platform licensed from Amgen, to launch multiple oncology products that address colorectal cancer with minimal residual disease (CRC MRD), tenosynovial giant cell tumors (TGCT), and an antibody-drug-conjugate construction for acute myeloid leukemia (AML) and solid tumors. AmMax has a very experienced management team, led by Dr. Larry Hsu, co-founder and former CEO of Impax Laboratories, Inc., which he successfully built into a fully integrated multi-billion dollar publicly traded pharmaceutical company. With broad experience across therapeutic areas and therapeutic modalities, the AmMax team is strong in execution and has collectively brought multiple BLAs, NDAs and MAAs to approval and commercialization. With a seasoned management team, a versatile technology platform and a robust pipeline, AmMax is poised to grow into a leading biotech company. For more on AmMax Bio and its pipeline, please visit the Company’s website at: www.AmMaxBio.com.

Cambridge, Massachusetts, United States

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located.

Shanghai, China

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a pipeline of 9 oncology programs at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.

Gunnels Wood Road, Stevenage, England SG12FX, GB

Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers.

Toronto, Canada

Regenerative Medicine company developing protein therapeutics modulating developmental signaling pathways with the goal of mobilizing tissue stem cells activity to unleash endogenous tissue repair capabilities.

San Carlos, California, United States

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.

Chongnoong Dong, Seoul-t'ukpyolsi, South Korea

APITBIO is a biotech company that specializes in antibody therapeutics research and development.

Stony Brook, New York, United States

Develops DNA Security Tags, Molecular diagnostics, and vaccines.COVID-19: Applied DNA and Takis Biotech completed the design of a diagnostic kit for SARS-COV-2 (the virus that causes the disease COVID-19) being developed for production via the company’s proprietary PCR-based DNA (LineaRx™) manufacturing process. They also work with Takis on vaccines. EUA (05/2020)

Au, Zurich, Switzerland

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Bellevue, Washington, United States

Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.

San Francisco Bay Area, California, United States

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Newtown Square, Pennsylvania, United States

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

San Diego, California, United States

At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego.

Princeton, New Jersey, United States

Aureka Biotechnologies aims to improve human health through digitalizing therapeutic discovery.

Lawrenceville, New Jersey, United States

Asana BioSciences, a clinical-stage biopharmaceutical company, was founded in 2014 with the mission to develop novel, clinically differentiated, best-in-class products that address unmet medical needs and provide new treatment options for cancer patients and those suffering from inflammatory conditions. Seven successful INDs were filed in a short span after founding of Asana and multiple clinical proof of concepts studies have been completed in oncology and immunology/inflammation therapeutic categories. Gusacitinib (ASN002), Asana’s lead immunology asset, is entering phase 3 development. Asana’s lead oncology asset (ASN007 or ERAS-007) has completed phase 1 trials in cancer patients. Multiple drugs from Asana’s portfolio have already been out-licensed/partnered with other biotech companies for further development and commercialization.

Rue de la Science, 8, Marche-en-Famenne, Luxembourg, BE, 6900

ATB Therapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

San Carlos, California, United States of America

We are a biopharmaceutical company developing novel therapeutics based on a deep understanding of the human immune response.

Bangalore, Karnataka, India

Aurigene Pharmaceutical Services is leading contract research, development, and manufacturing organization (CDMO). Built on the legacy of accelerating innovation and backed by a vast experience in drug discovery and development our mission is to relentlessly work for the success of our clients and to build long term relationships through a holistic approach to accelerate the journey of a molecule from laboratory to market. By providing access to our resources, knowledge and experience, we create success for our clients and ultimately patients. We offer integrated and standalone services for medicinal chemistry, biology, preclinical services, DMPK studies, development and manufacturing for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. A differentiating factor is the integrated API and formulations service that spans from key starting material, advanced intermediates, APIs to finished products such as oral solids, sterile products, nasal solutions etc. Our development services in India are complemented by cGMP commercial manufacturing facilities in the UK, Mexico, USA and India.

Saint Thomas, United States Virgin Islands

Auven Therapeutics is a private equity firm pursuing an innovative life science investment strategy. Although it utilizes a fund structure, it also has an internal drug development company that allows it to more effectively manage drug development and grow the value of its therapeutic assets.

Wetherby, England, United Kingdom

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

San Diego, California, United States

AvantGen is a biotechnology company dedicated in accelerating antibody-based therapeutics for their scientific partners by using innovative platforms. Based in San Diego, the fun and collaborative team is steadfast in this pursuit.